Renal cell carcinoma (RCC) management has been transformed in 2026 by new adjuvant combinations, long-term IO durability data, and two practice-shaping trials from ASCO GU 2026 — LIGHTSPARK-022 and LIGHTSPARK-011 — that are already reshaping how fellows think about sequencing therapy from resection through second-line metastatic disease. Whether you are managing your first post-nephrectomy patient or deciding between frontline IO+TKI combinations, this guide gives you the clinical framework you need. For a broader approach to staying current with rapidly changing oncology data, see how to read the NCCN guidelines effectively as a heme/onc learner.
TL;DR
Pembrolizumab (KEYNOTE-564) is the current adjuvant standard after nephrectomy for intermediate-high and high-risk RCC, with a confirmed OS benefit (91.2% vs 86% at 4 years); offer it to your highest-risk patients first.
LIGHTSPARK-022 (ASCO GU 2026) showed pembrolizumab + belzutifan improved DFS vs pembro alone in the adjuvant setting, but grade ≥3 AEs more than doubled — OS data are pending, so this is not yet standard of care.
For de novo metastatic clear-cell RCC, IO+TKI combinations (cabozantinib+nivolumab, lenvatinib+pembrolizumab) or dual IO (nivolumab+ipilimumab) are all frontline options; choose based on disease bulk, pace, and comorbidities rather than IMDC category alone.
LIGHTSPARK-011 (ASCO GU 2026) showed lenvatinib+belzutifan achieved a 52.6% ORR vs 40% for cabozantinib monotherapy in the post-IO setting, with a doubled duration of response (23 vs 12 months) — this will likely become a go-to second-line option.
Belzutifan's key toxicities are anemia (manage with ESAs and iron repletion) and hypoxia (home pulse oximetry, hold drug early if trending down); also monitor for cardiac dysfunction with an echo.
No validated biomarker guides adjuvant treatment selection in RCC yet — use recurrence calculators like the Fox Chase nomogram to personalize shared decision-making with patients.
What Is the Current Adjuvant Standard After Nephrectomy for RCC?
Pembrolizumab is the only FDA-approved adjuvant therapy for resected RCC, based on KEYNOTE-564. It is indicated for intermediate-high risk (T2 grade 4 or sarcomatoid differentiation, or T3 any grade) and high-risk disease (T4 any grade, or any node-positive disease), as well as M1 patients rendered NED within one year of diagnosis. The 4-year OS data now confirm a survival advantage: 91.2% vs 86.0% in favor of pembrolizumab — the first OS benefit demonstrated in the adjuvant RCC setting.
In practice, though, these conversations are among the longest in clinic. The bar for adjuvant therapy is higher when a patient may already be cured by surgery. Without validated biomarkers or reliable MRD assays in RCC — unlike some other tumor types where ctDNA is beginning to guide decisions — you are working from population-level risk estimates. Tools like the Fox Chase nomogram can help individualize recurrence risk discussion at the bedside. Most experienced oncologists reserve adjuvant pembrolizumab for their truly highest-risk patients: those with sarcomatoid features, significant IVC invasion, or M1 NED disease.
Should You Add Belzutifan to Adjuvant Pembrolizumab? What LIGHTSPARK-022 Showed
LIGHTSPARK-022, presented at ASCO GU 2026, is the largest randomized phase 3 trial ever conducted in the adjuvant RCC setting (n=1,841), and the first to use an active comparator — pembrolizumab monotherapy — rather than placebo. The combination arm added belzutifan, a HIF-2α inhibitor that works through a distinct mechanism from immunotherapy, to pembrolizumab. DFS curves separated early and stayed separated, with subgroup analyses consistently favoring the combination. Notably, the trial included M1 NED patients up to two years out from surgery, making the enrolled population somewhat higher-risk than KEYNOTE-564.
The problem is toxicity. While the combination did not increase immune-related adverse events, belzutifan caused anemia and hypoxia in a meaningful proportion of patients. Grade ≥3 adverse events were more than double in the combination arm compared to pembrolizumab monotherapy. Patients with baseline hemoglobin below 10 g/dL or underlying pulmonary disease were excluded from the trial — a signal about who can actually tolerate this regimen. In community practice, this translates to more EPO support, potential transfusions, and home pulse oximetry with twice-daily readings to catch hypoxia before it becomes dangerous.
OS data are not yet mature, and patient-reported outcomes (PROs) have not been presented. Without knowing whether the DFS benefit translates into a survival gain — and without data on how patients feel on treatment — most experts are waiting before adopting this combination as a new standard. NCCN guidelines have not yet incorporated belzutifan into the adjuvant pathway. The discussion in your clinic will be harder than the KEYNOTE-564 conversation: more benefit signaling, but more toxicity, and no OS anchor yet.
What Are the Frontline Treatment Options for Metastatic Renal Cell Carcinoma?
For de novo metastatic clear-cell RCC, multiple combination regimens have demonstrated survival superiority over sunitinib monotherapy and are all considered acceptable first-line options in 2026. These include nivolumab+ipilimumab (CheckMate 214), cabozantinib+nivolumab (CheckMate 9ER), lenvatinib+pembrolizumab (CLEAR), and axitinib+pembrolizumab (KEYNOTE-426). Rather than mechanically applying IMDC criteria to pick a regimen, most experienced clinicians use IMDC primarily for prognostication — it helps you understand disease biology and set expectations, but it does not cleanly direct which IO combination to use.
The key decision axis is pace of disease and whether you can afford to wait for a durable response or need tumor shrinkage quickly. If a patient has high-burden, rapidly progressive disease and you are not sure you will get a second chance to treat them, prioritize the regimen with the highest objective response rate and best tolerability: IO+TKI combinations typically deliver faster, broader responses across the molecular heterogeneity of kidney cancer. If it is low-volume disease — lymph nodes, lungs — and the patient is fit, you might reasonably shoot for the durability tail of nivolumab+ipilimumab, particularly given the impressive CheckMate 214 long-term data showing durable benefit in intermediate- and poor-risk patients. Nivolumab+ipilimumab is also preferred in sarcomatoid RCC, where immunotherapy response rates are particularly high.
How Do You Choose Between IO+TKI Combinations?
Cabozantinib+nivolumab and lenvatinib+pembrolizumab are the two most commonly used IO+TKI regimens in frontline metastatic RCC in 2026. The practical difference comes down to toxicity profile rather than efficacy. Cabozantinib at 40 mg daily (the combination dose, lower than the 60 mg monotherapy dose) is generally well-tolerated, with hand-foot syndrome and GI distress as the main issues. Lenvatinib at 18 mg daily (vs 20 mg as monotherapy) carries a higher response rate but frequently requires dose reductions — hypertension can be difficult to control, and patients often need structured dose-reduction counseling from day one. Counsel patients upfront that a 3-weeks-on/1-week-off approach or early dose reduction is not treatment failure — it is good medicine.
Patient comorbidities often tip the decision: choose the TKI partner based on what your patient can tolerate. Nivolumab is now available as a subcutaneous formulation, which reduces clinic burden. Axitinib+pembrolizumab is another reasonable choice, particularly when lenvatinib toxicity is a concern, with durable data from KEYNOTE-426. NGS testing upfront is generally not used to guide IO+TKI selection in clear-cell RCC, though it is important for identifying rare mutations and non-clear-cell histologies — for a deeper dive on molecular testing interpretation, see our guide to NGS and molecular diagnostics for clinical decision-making.
What Do You Do When Disease Recurs or Progresses After Adjuvant Pembrolizumab?
Progression after adjuvant pembrolizumab is genuinely challenging — there is no high-quality randomized data to guide rechallenge with PD-1 therapy. The conceptual problem is that PD-1 receptor occupancy from pembrolizumab can persist in peripheral blood for months after the last dose, so a patient progressing on or shortly after adjuvant IO may have disease that is truly refractory to that mechanism. Most clinicians use an arbitrary threshold: if a patient progressed actively while on pembrolizumab or within 3–6 months of completing it, they are unlikely to benefit from PD-1 rechallenge, and you should move to an IO+TKI or TKI-only backbone. If they have been off therapy for a year or more, giving the benefit of the doubt and including IO in the next regimen is reasonable, though still empirical.
The best available data for rechallenge come from CONTACT-03 and TeNevo2, but those trials enrolled patients who progressed after prior IO in the metastatic setting — not after adjuvant PD-1 when patients had no measurable disease. The extrapolation is imperfect. The field is actively studying this question, and structured data will likely be available in the next 2–3 years.
What Is the Second-Line Standard After IO-Based Frontline Therapy?
After progression on a frontline IO-containing regimen, cabozantinib monotherapy, lenvatinib monotherapy, and axitinib have all been used, with VEGFR TKI therapy representing the backbone of second-line RCC. The key ASCO GU 2026 data that changes the calculus here is LIGHTSPARK-011.
How Do You Manage Belzutifan Toxicity in Practice?
Belzutifan's two signature toxicities — anemia and hypoxia — stem from its HIF-2α inhibition mechanism, which reduces erythropoietin production and can impair oxygen-sensing pathways. For anemia: check iron stores at baseline, treat iron deficiency aggressively with IV iron if needed, and start erythropoiesis-stimulating agents (ESAs) early rather than reactively. For hypoxia: send patients home with a pulse oximeter and have them take twice-daily readings. If you see a downward trend in oxygen saturation, interrupt belzutifan early — do not wait for the patient to become symptomatic. The LIGHTSPARK-011 data also revealed a low but real rate of cardiac dysfunction (approximately 7%), so consider a baseline echocardiogram and a follow-up echo, particularly if you are intensifying therapy. This kind of proactive toxicity management is a skill you will develop across all your rotations
In the community oncology setting, you may not have the same monitoring infrastructure as an academic trial site, which means building explicit protocols for anemia checks, oximetry follow-up, and dose interruption thresholds is essential before your first patient starts treatment. Financial toxicity is also real: belzutifan is expensive, and combination regimens further compound cost burden — this needs to be part of the shared decision-making conversation, especially in the adjuvant setting where the OS benefit is not yet established. The ASCO financial toxicity framework is a useful reference when counseling patients.
How Should You Think About Overall Renal Cell Carcinoma Management Strategy in 2026?
Kidney cancer management in 2026 demands individualized, risk-stratified decision-making at every inflection point. In the adjuvant setting, pembrolizumab is the established standard — offer it to your highest-risk patients while using validated nomograms to guide shared decision-making, and wait for OS and PRO data from LIGHTSPARK-022 before adding belzutifan outside of a clinical trial. In the frontline metastatic setting, IO+TKI combinations or dual IO (for eligible patients with low-volume disease or sarcomatoid histology) remain the pillars of care. For sequencing, think about what TKI your patient has or has not been exposed to, and plan ahead — the sequence matters because resistance mechanisms evolve. For a broader approach to reading conference data and applying it at the bedside, see how to maximize the 2026 meeting season as a heme/onc fellow.
In the second-line and beyond, LIGHTSPARK-011 has opened a new option with lenvatinib+belzutifan that doubles response durability compared to cabozantinib alone, at the cost of belzutifan-specific toxicities that require active management. Board-level knowledge of RCC is increasingly important for fellows heading into ABIM exams — for a structured study plan covering GU malignancies and other high-yield topics, see the 6-month ABIM hematology and oncology board exam study plan.
Frequently Asked Questions
Who qualifies for adjuvant pembrolizumab after nephrectomy for RCC?
Adjuvant pembrolizumab (KEYNOTE-564) is FDA-approved for intermediate-high risk (T2 grade 4 or sarcomatoid features, or T3 any grade), high-risk (T4 or node-positive), and M1 NED disease resected within one year. In practice, most oncologists offer it selectively to the highest-risk patients — those with sarcomatoid differentiation, significant IVC invasion, or M1 NED status — given the lack of biomarkers to identify who benefits most.
What is the difference between LIGHTSPARK-022 and LIGHTSPARK-011?
LIGHTSPARK-022 evaluated pembrolizumab+belzutifan vs pembrolizumab alone in the adjuvant setting after nephrectomy. It showed a DFS benefit but also more than doubled grade ≥3 toxicity; OS data are pending. LIGHTSPARK-011 evaluated lenvatinib+belzutifan vs cabozantinib in the post-IO metastatic setting and showed a 52.6% ORR and a doubling of median duration of response (23 vs 12 months), making it a likely new standard second-line option.
Should I use nivolumab+ipilimumab or an IO+TKI combination as frontline therapy for metastatic RCC?
Both are reasonable, and your choice should be driven by disease pace and patient fitness rather than IMDC category alone. If the patient needs a fast response due to high disease burden, IO+TKI combos (cabo+nivo or lenva+pembro) generally deliver higher ORRs. If the patient has low-volume disease and you can afford to wait for durability, nivo+ipi offers a notable long-term tail — particularly in sarcomatoid disease and intermediate/poor-risk patients.
How do you manage belzutifan toxicity in clinical practice?
Belzutifan's main toxicities are anemia (manage with iron repletion and ESAs) and hypoxia (home pulse oximetry with twice-daily readings, hold drug if O2 saturation trends down). Exclude patients with baseline Hgb below 10 g/dL or pulmonary comorbidities. Also monitor cardiac function with an echo at baseline and during treatment, as a small percentage of patients develop cardiac dysfunction. Proactive protocols for dose interruption are essential, especially in community settings.
Is there a role for ctDNA or MRD testing to guide adjuvant therapy decisions in RCC?
Not in routine practice as of 2026. Unlike some hematologic malignancies and colorectal cancer where ctDNA is beginning to guide adjuvant decisions, validated MRD assays are not yet part of RCC clinical practice. Early data around KIM-1 as a potential biomarker are emerging but not ready for clinical adoption. Until validated biomarkers arrive, recurrence risk calculators such as the Fox Chase nomogram remain the best tool for personalizing adjuvant treatment discussions.
Ready to test your renal cell carcinoma and GU oncology knowledge with ABIM-style board questions? MeducationAI offers heme/onc-specific question banks, visual learning tools, and AI-powered explanations built for fellows. Start your free trial at meducationai.com.
